Microfluidic Nano-Capture Technology achieves precise capture of target cells within minute samples by combining chip-level negative-pressure adsorption channels with antibodies specific to cell surface markers (e.g., Epithelial Cell Adhesion Molecule for tumor cells, αSMA for CAFs). The gene discussed is ACTA1; the disease is neoplasm.